November 2, 2021 01:00 PM EDTUpdated November 3, 04:59 PM

MarketingRx roundup: J&J boosts health equity goals in 6-city challenge; Allergan Aesthetics kicks off breast cancer efforts

Beth Snyder Bulik

Senior Editor

Johnson & Johnson is looking for big ideas from small entrepreneurs. Spurred by the pandemic health inequities and ongoing racial injustice in local communities, J …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MarketingRx roundup: J&J boosts health equity goals in 6-city challenge; Allergan Aesthetics kicks off breast cancer efforts

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Mar­ket­ingRx roundup: J&J boosts health eq­ui­ty goals in 6-city chal­lenge; Al­ler­gan Aes­thet­ics kicks off breast can­cer ef­forts

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

MarketingRx roundup: J&J boosts health equity goals in 6-city challenge; Allergan Aesthetics kicks off breast cancer efforts

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam